Raimond Heukers

Nanobody-liposomes as novel cancer vaccine platform to efficiently stimulate T cell immunity

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies

Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions

Selective targeting of ligand-dependent and -independent signaling by GPCR conformation-specific anti-US28 intrabodies

Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells

VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells

The constitutive activity of the virally encoded chemokine receptor US28 accelerates glioblastoma growth

Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions

CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry

Class<scp>III</scp>antiarrhythmic drugs amiodarone and dronedarone impair<scp>K_IR</scp>2.1 backward trafficking

EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling

Nanobody–photosensitizer conjugates for targeted photodynamic therapy

Targeting tumors with nanobodies for cancer imaging and therapy

Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles

EGFR endocytosis requires its kinase activity and N-terminal transmembrane dimerization motif

Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways

Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells

Inhibiting the clathrin-mediated endocytosis pathway rescues KIR2.1 downregulation by pentamidine